Company news

Adc Therapeutics Sa (NYSE:ADCT) news

Every Adc Therapeutics Sa press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Adc Therapeutics Sa stock analysis →

Press releases & updates

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

August 13, 2026

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial

June 30, 2026

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

June 24, 2026

ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapse...

June 3, 2026

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

May 4, 2026

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

April 27, 2026

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

March 10, 2026

ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

March 3, 2026

ADC Therapeutics to Participate in March Investor Conferences

February 24, 2026

ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement

February 23, 2026

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

February 2, 2026

ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

January 8, 2026

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 8, 2026

ADC Therapeutics Announces New Employee Inducement Grant

January 2, 2026

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Support...

December 3, 2025

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

December 2, 2025

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

November 10, 2025

ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025

November 3, 2025

ADC Therapeutics to Present at November Investor Conferences

October 27, 2025

ADC Therapeutics Announces $60 Million Private Placement

October 13, 2025

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

August 27, 2025

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

August 12, 2025

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

August 5, 2025

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

July 1, 2025

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th Internatio...

June 16, 2025

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

June 12, 2025

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

June 12, 2025

ADC Therapeutics to Present at Upcoming Investor Conferences

May 15, 2025

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

May 14, 2025

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and...

May 14, 2025

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

May 8, 2025

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

April 28, 2025

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

April 1, 2025

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

March 27, 2025

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

March 25, 2025

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

March 20, 2025